Baird downgrades Doximity stock rating on AI investment concerns

Baird downgraded Doximity to Neutral from Outperform and cut its price target to $18 from $40, citing a long payback period for AI investments, slowing growth, and rising competitive and regulatory pressure. The stock trades at $23.39, nearly 61% below last year’s level, while 17 analysts have lowered earnings estimates and the company has only about 65% of its fiscal 2027 guidance range booked. Recent Q4 2026 results also missed EPS expectations at $0.26 versus $0.28, even as revenue slightly beat at $145.4 million.

Analysis

The market is starting to price DOCS less as a durable software compounder and more as a cyclical ad budget lever with an AI capex overlay. That matters because once a name loses “must-own” status, multiple compression can persist even if top-line growth stabilizes; the path back usually requires several quarters of clean beats, not one quarter of modest revenue outperformance. The key second-order effect is on future hiring and product cadence: a reduced valuation currency constrains the company’s ability to use equity for talent, which can slow product execution just as competitors are becoming more aggressive.

The biggest near-term risk is not absolute decline in the business, but a reset in the implied durability of growth. If fiscal 2027 is only partially booked, the company is effectively exposed to a short-duration demand book, which makes every incremental ad spending wobble or pharma procurement delay disproportionately important over the next 1-2 quarters. In this setup, the stock can overshoot to the downside because fixed-cost AI investment creates operating leverage in reverse; small growth misses translate into larger EPS revisions and a lower acceptable multiple.

The contrarian angle is that the selloff may be pricing in too much linearity in AI payback risk. If the new tools materially improve physician engagement or ad conversion, the upside won’t show first in headline revenue—it will show in retention, lower churn, and better monetization per account over 2-4 quarters. That creates a potential asymmetry: the stock may remain weak near term, but any evidence of accelerating advertiser ROI could force a sharp repricing because expectations are now so depressed.

For competitors, the implication is broader than DOCS: any healthcare ad platform or workflow vendor pitching AI-heavy spend will face a higher proof threshold, which should favor balance-sheet-light names with clearer ROI and penalize experimental product launches. The broader sector read-through is that healthcare digital advertising is entering a tougher procurement cycle, so budgets may shift toward channels with measurable conversion rather than reach alone.

Key Decisions for Investors

• Short DOCS on any rally back toward prior support; use a 1-3 month horizon and keep a tight stop above the post-downgrade gap fill, since the next catalyst is likely further estimate cuts rather than a rerating.
• If already bearish DOCS, prefer put spreads over outright puts for the next 60-90 days; the setup is fundamentally weak, but implied vol may already reflect elevated event risk, making defined-risk downside cheaper.
• Pair trade: long a higher-quality healthcare software name with clearer recurring demand and short DOCS to isolate execution risk; look for 6-12 weeks of relative underperformance if ad budgets remain soft.
• Avoid buying the dip until there is evidence of upward revisions in fiscal 2027 bookings or advertiser trends; absent that, this is a value trap rather than a classic reset.
• For event-driven traders, watch the next quarterly print for margin guidance more than revenue; any sign that AI investment is not translating into operating leverage is a strong add-to-short signal.